key: cord-1037942-ko7jde0b
authors: Arum, Chiedozie; Fraser, Hannah; Artenie, Andreea Adelina; Bivegete, Sandra; Trickey, Adam; Alary, Michel; Astemborski, Jacquie; Iversen, Jennifer; Lim, Aaron G; MacGregor, Louis; Morris, Meghan; Ong, Jason J; Platt, Lucy; Sack-Davis, Rachel; van Santen, Daniela K; Solomon, Sunil S; Sypsa, Vana; Valencia, Jorge; Van Den Boom, Wijnand; Walker, Josephine G; Ward, Zoe; Stone, Jack; Vickerman, Peter
title: Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
date: 2021-03-26
journal: Lancet Public Health
DOI: 10.1016/s2468-2667(21)00013-x
sha: fbbaa41c53b372d37c0f951742eb31b271cee612
doc_id: 1037942
cord_uid: ko7jde0b

BACKGROUND: People who inject drugs (PWID) are at increased risk for HIV and hepatitis C virus (HCV) infection and also have high levels of homelessness and unstable housing. We assessed whether homelessness or unstable housing is associated with an increased risk of HIV or HCV acquisition among PWID compared with PWID who are not homeless or are stably housed. METHODS: In this systematic review and meta-analysis, we updated an existing database of HIV and HCV incidence studies published between Jan 1, 2000, and June 13, 2017. Using the same strategy as for this existing database, we searched MEDLINE, Embase, and PsycINFO for studies, including conference abstracts, published between June 13, 2017, and Sept 14, 2020, that estimated HIV or HCV incidence, or both, among community-recruited PWID. We only included studies reporting original results without restrictions to study design or language. We contacted authors of studies that reported HIV or HCV incidence, or both, but did not report on an association with homelessness or unstable housing, to request crude data and, where possible, adjusted effect estimates. We extracted effect estimates and pooled data using random-effects meta-analyses to quantify the associations between recent (current or within the past year) homelessness or unstable housing compared with not recent homelessness or unstable housing, and risk of HIV or HCV acquisition. We assessed risk of bias using the Newcastle-Ottawa Scale and between-study heterogeneity using the I(2) statistic and p value for heterogeneity. FINDINGS: We identified 14 351 references in our database search, of which 392 were subjected to full-text review alongside 277 studies from our existing database. Of these studies, 55 studies met inclusion criteria. We contacted the authors of 227 studies that reported HIV or HCV incidence in PWID but did not report association with the exposure of interest and obtained 48 unpublished estimates from 21 studies. After removal of duplicate data, we included 37 studies with 70 estimates (26 for HIV; 44 for HCV). Studies originated from 16 countries including in North America, Europe, Australia, east Africa, and Asia. Pooling unadjusted estimates, recent homelessness or unstable housing was associated with an increased risk of acquiring HIV (crude relative risk [cRR] 1·55 [95% CI 1·23–1·95; p=0·0002]; I(2)= 62·7%; n=17) and HCV (1·65 [1·44–1·90; p<0·0001]; I(2)= 44·8%; n=28]) among PWID compared with those who were not homeless or were stably housed. Associations for both HIV and HCV persisted when pooling adjusted estimates (adjusted relative risk for HIV: 1·39 [95% CI 1·06–1·84; p=0·019]; I(2)= 65·5%; n=9; and for HCV: 1·64 [1·43–1·89; p<0·0001]; I(2)= 9·6%; n=14). For risk of HIV acquisition, the association for unstable housing (cRR 1·82 [1·13–2·95; p=0·014]; n=5) was higher than for homelessness (1·44 [1·13–1·83; p=0·0036]; n=12), whereas no difference was seen between these outcomes for risk of HCV acquisition (1·72 [1·48–1·99; p<0·0001] for unstable housing, 1·66 [1·37–2·00; p<0·0001] for homelessness). INTERPRETATION: Homelessness and unstable housing are associated with increased risk of HIV and HCV acquisition among PWID. Our findings support the development of interventions that simultaneously address homelessness and unstable housing and HIV and HCV transmission in this population. FUNDING: National Institute for Health Research, National Institute on Drug Abuse, National Institute of Allergy and Infectious Diseases, and Commonwealth Scholarship Commission.

Endnote X9 will be used to catalogue search results. These will be de-duplicated using the 'find duplicate' feature. Titles and abstracts will be screened based on the inclusion criteria. Full text of relevant references will be obtained and for studies that could not be explicitly excluded based on their titles or abstracts for a more thorough screening. The full text will be used to determine the eligibility for inclusion and for exclusion of studies, with clear reasons documented. In order to facilitate the creation of a PRISMA flow diagram, the 'group' functionality will be used to track results from each stage of the selection process. The selected list of references to be included in the review will be further stratified into those relating to HIV or HCV or both.

All references will be screened by one author through to the full text stage. In addition, 10% of the reference will be screened by multiple authors through to the full text stage. In a case of inconsistences between the lists of accepted references, the remaining references will be double screened. Any ensuing discord that cannot be resolved by discussion will be adjudicated by a third author.

Data from selected references will be extracted using Microsoft Excel 2016. This will be done by one author and will be checked for accuracy by a second author with any discord not resolvable by discussion adjudicated by a third. For studies on incidence of HIV or HCV among PWID that do not report on the outcome of interests (effect of homelessness or unstable housing on HIV or HCV incidence) or with ambiguous effect estimates, the authors will be contacted to request unpublished effect estimates or to resolve any ambiguities.

Data will be extracted on: ▪ Lead author, review title or unique identifier and date ▪ Study design (including sampling methods, participants, and attrition rate) ▪ Study location ▪ Study setting ▪ Study period (over which follow-ups are performed) ▪ Baseline sample size ▪ Study inclusion and exclusion criteria (including definition of PWID, e.g. injecting in the last 30 days) ▪ Attrition rate with comments on attrition. ▪ Methods of assessment of HIV/HCV infection and HCV re-infection ▪ Age of participants (median/mean) ▪ Sex of participants (proportion of males/ females) ▪ Duration of injecting of participants (mean/median) ▪ Incarceration history (proportion ever incarcerated) ▪ OST coverage ▪ Proportion of homeless participants ▪ Definition of homelessness ▪ Duration of follow up, overall and by housing status ▪ Outcome measure (HCV or HIV seroconversion); overall and by housing status ▪ Unadjusted and adjusted effect size (incidence rate ratio (IRR); odds ratio (OR); hazard ratio (HR); and precision (e.g. 95% confidence interval (CI)). ▪ Confounding factors used to adjust effect estimates ▪ Background HIV/HCV prevalence. ▪ Risk of bias scores.

The risk of bias will be assessed using the Newcastle-Ottawa Scale (NOS scale) for assessing quality of nonrandomized studies. The scale is designed to award a maximum of 9 stars to any study in relation to selection of participants, comparability of cohorts based on design and analysis, and methods of ascertainment of study outcomes. Confounding factors such as Opioid Substitution treatment (OST), stimulant injecting and recent incarceration will be adjusted for.

A descriptive summary of findings from selected studies will be included in the review bearing in mind that there may be considerable heterogeneity between studies. For studies with sufficiently similar effect estimates, a metaanalysis will be performed on the crude and adjusted effects of homelessness and unstable housing on incidence of HIV/HCV infection. A random effect meta-analysis will be adopted considering the expectation of some degree of heterogeneity between studies.

In order to explore whether observed differences in result from the studies are compatible with chance alone, heterogeneity will be examined through inspection of the forest plot, by a Chi 2 test and I-squared statistics. This will further be explored through subgroup analysis and sensitivity analysis.

To assess publication bias, funnel plots will be used to plot the study effect size against sample size. Funnel plot asymmetry will be assessed by Egger's test.

Where enough data are available, subgroup analysis and meta-regression will be undertaken to compare outcomes by: ▪ Region ▪ Year of study ▪ Mean age and duration of injecting ▪ Proportion of study sample females ▪ Definition of homelessness ▪ Proportion of PWID with recent history of incarceration ▪ OST coverage at baseline ▪ Publication statuspublished or unpublished.

All variables found to be significant in the univariable meta-regression will be included in multi-variate analysis if there are enough studies. Similarly, analysis of confounding will be undertaken using subgroup analyses and metaregression to compare adjusted effect estimates based on whether they were adjusted for:

▪ Current/recent OST coverage ▪ Recent history of incarceration ▪ Current/recent stimulant injecting

Sensitivity analyses will be performed to assess the impact of including in separate meta-analyses only: studies at low/moderate risk of bias; longitudinal studies; studies reporting hazard ratios; studies with at least 90% recent injectors (injected within last 12 months) at baseline.

Medline database search strategy to identify relevant studies. Keywords are listed in regular type and medical subject headings (Mesh) terms are in Bold. Data were extracted from included studies using Microsoft Excel 2016 for Windows. Key characteristics that were extracted from individual study included: publication year, study location (city and country), study period (start and end period), study design, cohort name, cohort recruitment sites and methodology, study inclusion and exclusion criteria, duration of follow-up(average), attrition (with comments), methods of assessment of HIV and HCV incident infection and/or reinfection, risk of bias assessment, baseline study characteristics (sample size, proportion who are recent or ever injectors, definition of recent injection, number and proportion of female participants, number and proportion of participants with history of ever been incarcerated, number and proportion of participants with recent history of incarceration, mean/median age and duration of injecting, baseline HIV and HCV prevalence, baseline OST coverage, definition of recent homelessness or unstable housing, proportion homeless at baseline, number and rate of incident infection and number of person-years of follow-up (stratified by housing status: homeless vs not homeless), crude and adjusted effect estimates with 95% uncertainty interval, variables included in the adjusted analysis (with definitions). 41 IDUs were recruited from a range of field stations across South Wales. These included treatment ser-vices, needle and syringe exchange services and home-less hostels. Individuals were also approached on the street. Drug injectors were invited to enter the study by professional staff, by researchers and by word of mouth between study participants. Recruitment was thus opportunistic but made use of existing social and drug-using networks. The target criteria for inclusion in the study were being a current or a recent drug injector. 24 ARYS participants were recruited through snowball sampling and extensive street-based outreach methods. The street-based recruitment approach produced a sample of youth who spent extensive time on the streets (a large proportion of whom were homeless) of Vancouver and from youth agencies and services. To be eligible, participants at recruitment must have been aged 14-26 years; used illicit drugs other than marijuana in the past 30 days; be "street involved," defined as having been homeless in the past 6 months or recently having used a service for street-involved youth (e.g., housing or nutrition support); and had to provide written informed consent; and had to provide written informed consent. For this analysis, participants were eligible as of the first visit they reported injection in the previous 6 months and if they were seronegative for anti-HCV. is an open prospective community-recruited cohort of PWID in Vancouver, Canada. Beginning in May 1996, active PWID (i.e. those who reported injecting drugs in the previous month) were recruited in the Greater Vancouver region on an ongoing basis throughout the study period. Recruitment strategies employ extensive street-based outreach and ''snowball'' sampling approaches. Given VIDUS is an open cohort, new participants were continuously enrolled in the cohort over the study period to replace those who died or were lost to follow-up. All participants were recruited through street outreach, word of mouth, and self-referral, and provided written informed consent prior to entering the study. Participants were eligible if they had injected illicit drugs at least once in the previous month, resided in the greater Vancouver region, and provided written informed consent. For this analysis, participants were eligible if they were seronegative for anti-HCV. 42 RAVEN Study, beginning in June 1994, cohort study subjects were recruited from six drug treatment programs and from social service, corrections, and drug-use assessment agencies. In each setting, subjects were systematically selected by use of a random-number based scheme from 1) all agency clients present during recruitment hours (nondrug treatment settings), or 2) all newly enrolled drug treatment clients. Series of random numbers between one and nine were issued to interviewers who would select the nth client as he or she entered the agency or appeared on client lists. Eligibility criteria included having injected an illicit drug in the previous year, being English or Spanish speaking, being 14 years or older, and not being already enrolled in the study. 46 London Cohort, Recruitment was done in the community settings. In 2001, we recruited from community settings mainly in London, but also in Brighton, 428 injecting drug users who were aged below 30 years or had been injecting for six years or fewer. All had injected in the previous four weeks and could provide addresses for follow up. 50 France Cohort, the participants recruited were drug-user attendees of six care centres in Northern and Eastern France. Eligible participants were those who had injected drugs at least once in their lifetime and whose HCV serology was presumed to be negative. Sixty-three persons positive for anti-HCV and 32 whose serological status was unknown were excluded from follow-up. Of the 231 HCV antibody negative IDUs enrolled in the study, three (2%) died and 63 (27%) did not undergo a final serum test and were excluded from the analysis.

Unstable housing in the past 3 months IRR 2.20 (0.51-7.22)

Maher et al (unpublished) 51 HCVC, Participants were recruited using a variety of strategies (direct approaches, word-of-mouth and fliers) designed to identify a broad cross-section of potential participants across a range of settings, including street-based outreach, local methadone and sexual health clinics and NSPs. Eligibility criteria include injected drugs in the last 6 months and anti-HCV serostatus not known to be positive. Individuals that tested antibody HCV negative were enrolled in the study. 57 The CEDAR Project, Participants living primarily in the downtown areas of both cities of Vancouver and Prince George, British Columbia were recruited through referral by health care providers, community outreach and word of mouth. Eligibility criteria for study entry included age 14 to 30 years and to have smoked or injected illicit drugs, aside from marijuana, in the month prior to enrolment. The Cedar Project cohort includes 605 participants in total, however this study included only participants who reported injection drug use, were HCV negative at baseline, reported injection drug use and who returned for at least one of eight follow-up interviews up to December 2008 (n = 148).

Homelessness in the past 6 months HR 1.26 (0.83-1.90)

ARISTOTLE HCV-HIV, Participants were recruited through respondent-driven sampling. A dual incentive system was used in which participants received incentives for participating in the programme (primary incentives) as well as for recruiting others (secondary incentives). Seeds were recruited by staff of the Greek Organization Against Drugs (OKANA) who had experience in working with the target population. The programme itself was implemented in a building of the OKANA, located in the centre of Athens. The staff included a physician, inter-viewers with prior experience with the target population and a psychologist and two social workers. A flow manager was responsible for maintaining the flow of participants and ensuring that participants completed each of the steps of the process on a firstcome, first-served basis. Five RDS rounds were implemented. The selection of seeds was based on whether the candidates were well connected to other members of the target population, liked by their peers and with motivation to the programme. The aim was to enrol seeds diverse in terms of country of origin, gender and HIV status to ensure reaching equilibrium. Respondents were eligible to participate if they presented a valid RDS coupon, had injected drugs without a prescription in the past 12 months, were 18 years of age and over, and resided in the Athens metropolitan area. A subset of PWID participated in multiple RDS rounds, allowing for assessment of HCV seroconversion. Only individuals with ≤2 years injecting were tested for anti-HCV. 59 CIDUS-Chicago study was conducted from storefront offices in four low-income Chicago neighbourhoods, each selected for its high concentration of drug users and its distinct racial and ethnic composition. Participants were recruited through street outreach, targeted advertising, and peer referrals. Street recruiting by former IDUs was done in areas such as youth hangouts, "shooting galleries" (places where drug users gather to inject drugs and perhaps be assisted in injecting), and illicit drug markets. Advertisements were placed in alternative magazines, in newspapers, and on college campuses. In a version of respondent-driven sampling, each newly interviewed participant received three coupons to distribute to eligible peers. When a peer redeemed one of these numbered coupons by enrolling in the study, the peer recruiter received an incentive fee of $10. Persons were enrolled in the study if they had proof of an eligible birthdate and reported having injected drugs in the past 6 months. Recent injection drug use was verified by inspecting for stigmata, such as scars or abscesses. When stigmata were absent, we interviewed enrolees to ascertain their familiarity with injection routines. This analysis included all participants who were susceptible to hepatitis C infection (negative for antibodies to HCV) at the initial visit.

Homelessness in the past 6 months HR 0.76 (0.31-1.86) aHR 0.63 (0.25-1.58) Adjusted for: Injection related risk exposures (sharing cookers, sharing cotton filters, sharing rinse water, sharing syringes), demographic covariates (high school diploma, suburban residence), drug use covariates (daily injection in the past 6 months, cocaine injection in the past 6 months).

Kabul Harm reduction program, Participants were recruited consecutively from areas of known drug user congregation and through harm reduction programs on scheduled days loosely apportioned by number of IDUs present at those locations, in a variant of time-location sampled. Recruitment sites were initially determined through formative work and through harm reduction programs, with locations adjusted monthly based on information from the participants, the harm reduction field workers, and pharmacists of new areas of congregation. Sites were distributed throughout Kabul city, with most sites in the western section of the city, consistent with reported and confirmed IDU presence throughout the study period. Eligibility was limited to IDUs who were aged ≥18 years; reported injecting drugs within the prior 30 days; residing in Kabul; Dari or Pashto speakers; and able to provide informed consent.

Homelessness in the past 6 months HR 0.76 (0.45-1.29)

Heroin-Itinere cohort, Street recruitment used targeted sampling and chain-referral methods. Each city was ethnographically mapped, providing a systematic frame with a wide range of street drug scenes. Anthropologists and social workers recruited initial seeds of nominators and participants. Incentive-driven procedures were used. Eligibility: 30 years or younger, use of heroin at least 12 days in the past 12 months and at least 1 day in the past 3 months. 63 SuperMix, Participants were recruited in urban Melbourne through respondent-driven sampling (RDS), street outreach and snowball sampling. Eligibility criteria included reporting regular heroin or methamphetamine injection in the past 6 months, being aged >18 years and providing a valid Medicare (Australia's universal healthcare system) number and contact details for data linkage. Two further eligibility criteria that aimed to recruit participants who were young (aged <31 years) and not prescribed OST were withdrawn during early recruitment owing to the ageing PWID population in Melbourne and fluctuating drug-market conditions. London Cohort, Recruitment was done in the community settings. In 2001, we recruited from community settings mainly in London, but also in Brighton, 428 injecting drug users who were aged below 30 years or had been injecting for six years or fewer. All had injected in the previous four weeks and could provide addresses for follow up.

Unstable housing in the past 12 months HR 0.94 (0.23-3.76) Kral et al. (2001) 65 Urban Health Study, Respondents were not recruited from institutional locations such as drug-treatment programmes, homeless shelters, correctional facilities, clinics, or hospitals. Active IDUs were recruited for the Urban Health Study in three inner-city communities in San Francisco from 1986, and in a fourth from 1996. 6-monthly surveys included 170-250 IDUs in each community.

We assessed data from 23 surveys done from 1986 to 1998. Respondents were recruited in natural settings with targeted sampling methods. Communities selected had high concentrations of IDUs according to drug-treatment admission data, police arrest data, direct observation, and earlier ethnographic studies. New respondents were screened for visible signs of recent subcutaneous or intravenous drug use (so-called tracks, or recently punctured veins). Respondents were permitted to participate in subsequent surveys irrespective of whether they had continued to inject drugs. Repeat respondents were identified by checking information against that held in a database on a lap-top computer. Every 6 months, a new sample was recruited; previous participants were not helped to return to the study. This method allowed us to assess new cases of HIV-1 infection from repeat visits of participants. The eligibility criterion was recent intravenous drug use (past 30 days). Respondents were not recruited from institutional locations such as drugtreatment programmes, homeless shelters, correctional facilities, clinics, or hospitals. ALIVE, Participants were recruited into the study from various agencies that served intravenous drug users. These agencies include Maryland Division of Parole and Probation, the Baltimore City Health Department's STD clinics, hospital emergency rooms, and homeless shelters in Baltimore. To extend recruitment beyond these agencies, outreach efforts were developed in collaboration with the Street Outreach AIDS Prevention (SOAP) Unit of the Health Education Resource Organization (HERO), a community AIDS education group in Maryland. The SOAP unit include ten recovered and recovering addicts who provide AIDS education to the inner-city community through contacts on the street. These workers distributed brochures and answered questions about the ALIVE study. Study staff also distributed brochures at local public housing projects and other public places known to be frequented by IVDUs. In summary, recruitment sources include: Word-of-mouth, drug treatment programs, HERO Street Outreach, Parole and Probation, STD Clinics, HIV clinics, and emergency rooms. Between 1998-1999, all participants acknowledged non-medical injection-drug use within the preceding 11 years, were >18 years of age, and were free of AIDS at entry into the study. Additional persons were recruited into this cohort in 1994-1995 (n 5 391), 1998 (n 5 244), and 2005-2008 (n 5 875). Some recruitment criteria changed over time. In the fourth period, persons were no longer required to be AIDS-free at entry. To replenish with active injectors, in 1994-1995, persons had to have injected in the preceding 3 Indian ICC Study, at each site, we partnered with nongovernmental organizations that provide services to PWIDs and conducted preliminary ethnographic work. We used respondent-driven sampling to recruit PWIDs, with the goal of recruiting 1000 participants from each site [14 -16] . We initiated recruitment at each site with two or three 'seeds'individuals identified in the ethnographic phase as well connected in the PWID communities. Individuals were eligible to participate if they were 18 years or older, reported 69 We conducted our study at three drop-in centres that provide basic harm reduction and social services to PWID exclusive of opiate substitution therapy. Excluded eight persons who were unable to understand the study objectives due to disabilities that precluded provision of informed consent. El Cuete III, Respondent-driven sampling (RDS) was used to recruit participants. Briefly, a diverse group of "seeds" (heterogeneous by age, gender, and neighbourhood) was selected and given uniquely coded coupons to refer their peers to the study. Waves of recruitment continued as subjects returning with coupons were given coupons to recruit members of their social networks. Recruitment and interviews were conducted by indigenous outreach workers through the use of a modified recreational vehicle and a storefront office. Eligibility criteria included being ≥18 years of age; having injected illicit drugs within the past month, as confirmed by inspection of injection stigmata ("track-marks"); ability to speak Spanish or English; being able to provide informed consent; and having no plans to permanently move out of the city in the next 18 months.

Unstable housing in the past 6 months HR 1.50 (0.55-4.07)

El Cuete IV, we sought to obtain representative samples of PWID in each site. Although we initially considered recruiting new cohorts of PWID using respondent driven sampling (RDS), due to issues of cost and the limited effectiveness of RDS at recruiting female PWID, we instead used targeted sampling consisting of street-based out-reach in diverse geographic areas For example, El Cuete IV outreach teams established temporary mobile recruitment sites (e.g., vans and tents) in ten distinct colonias (neighbourhoods) characterized by different physical risk environments and where PWID were known to spend time. Once situated in these neighbourhoods, outreach workers attempted to engage individuals in conversation, sometimes by offering HIV prevention materials or information (e.g., condoms, educational pamphlets). In both studies, eligibility criteria included the following characteristics: being at least 18 years of age, having evidence of injecting illicit drugs within the past month (i.e., confirmed by observation of track marks or other physical evidence of injecting), 3) being able to converse in English or Spanish, 4) currently residing in the study city with no plans to move away within 24 months from enrolment date, and 5) not currently participating in any intervention studies (although none to our knowledge were being conducted). Individuals with severe cognitive deficiencies or who were unwilling to provide informed consent were excluded, and PWID who met eligibility criteria but were too intoxicated to provide informed consent were rescheduled for rescreening at a later date.

Unstable housing in the past 6 months HR 2.10 (1.13-3.90)

ARISTOTLE, Participants were recruited through respondent-driven sampling. A dual incentive system was used in which participants received incentives for participating in the programme (primary incentives) as well as for recruiting others (secondary incentives). Seeds were recruited by staff of the Greek Organization Against Drugs (OKANA) who had experience in working with the target population. The programme itself was implemented in a building of the OKANA, located in the centre of Athens. The staff included a physician, inter-viewers with prior experience with the target population and a psychologist and two social workers. A flow manager was responsible for maintaining the flow of participants and ensuring that participants completed each of the steps of the process on a first-come, first-served basis. Five RDS rounds were implemented. The selection of seeds was based on whether the candidates were well connected to other members of the target population, liked by their peers and with motivation to the programme. The aim was to enrol seeds diverse in terms of country of origin, gender and HIV status to ensure reaching equilibrium. Respondents were eligible to participate if they presented a valid RDS coupon, had injected drugs without a prescription in the past 12 months, were 18 years of age and over, and resided in the Athens metropolitan area. A subset of PWID participated in multiple RDS rounds, allowing for assessment of HIV seroconversion. currently on OST program (Yes vs No), Injecting drug use behaviour: main substance of use (Heroin/Thai vs Cocaine/speedball), injecting drug use in past 1 month(No vs Yes), frequency of drug use (less than once weekly vs at least once weekly vs at least once daily), sharing syringes( never or rarely vs about half the time or more), use of drugs divided with a syringe that someone else had already used for injection (never or rarely vs about half the time or more).

Kabul Harm Reduction Program, Participants were recruited consecutively from areas of known drug user congregation and through harm reduction programs on scheduled days loosely apportioned by number of IDUs present at those locations, in a variant of time-location sampled. Recruitment sites were initially determined through formative work and through harm reduction programs, with locations adjusted monthly based on information from the participants, the harm reduction field workers, and pharmacists of new areas of congregation. Sites were distributed throughout Kabul city, with most sites in the western section of the city, consistent with reported and confirmed IDU presence throughout the study period. Eligibility was limited to IDUs who were aged ≥18 years; reported injecting drugs within the prior 30 days; residing in Kabul; Dari or Pashto speakers; and able to provide informed consent. Amsterdam Cohort Study, Participants were recruited mainly through low-threshold methadone programs (including a weekly sexually transmitted disease clinic for drug-using sex workers) and by word of mouth. 

Global mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study

Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study

Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review

HIV and risk environment for injecting drug users: the past, present, and future

Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis

High prevalence of latent tuberculosis and bloodborne virus infection in a homeless population

Homelessness and HIV risk behaviours among drug injectors in Puerto Rico

Prevalence of infections, HIV risk behaviours and factors associated with HIV infection among male injecting drug users attending needle/syringe exchange program in

Intensive injection cocaine use as primary risk factor in the Vancouver HIV-1 epidemic

HIV incidence, retention rate, and baseline predictors of HIV incidence and retention in a prospective cohort study of injecting drug users in Xinjiang, China

AIDS: results of a multicentre European study

Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study

A prognostic model for HIV seroconversion among injection drug users as a tool for stratification in clinical trials

Incarceration history and the risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis

What Works in inclusion health: overview of effective interventions for marginalised and excluded population?

High incidence of hepatitis C virus reinfection in a cohort of injecting drug users

Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland

Benzodiazepine Use and Hepatitis C Seroconversion in a Cohort of Persons Who Inject Drugs

A prognostic model for HIV seroconversion among injection drug users as a tool for stratification in clinical trials

Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users

Decrease of HIV incidence among injection drug users (IDU) in Montreal: Evidence from the saint-Luc cohort

Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users

Unstable housing associated risk behaviour, and increased risk for HIV infection among injection drug users. Health AND Place

Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver

Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey

Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting

Hepatitis C virus seroconversion among young injection drug users: relationships and risks

Benzodiazepine use as an independent risk factor for HIV infection in a Canadian setting

Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada

Incidence, and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination

Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting

Neighbourhood and HIV infection among IDU: place of residence independently predicts HIV infection among a cohort of injection drug users. Health AND Place

Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia

Binge drug use independently predicts HIV seroconversion among injection drug users: implications for public health strategies

Elevated rates of HIV infection among young Aboriginal injection drug users in a Canadian setting

HIV incidence and associated risk factors among young injection drug users

Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration

Temporal trends in the incidence of human immunodeficiency virus infection and risk behaviour among injection drug users in

Gender influences on hepatitis C incidence among street youth in a Canadian setting

High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention

The role of living context in prescription opioid injection and the associated risk of hepatitis C infection

HIV Incidence Among Men Who Have Sex with Men and Inject Drugs in a Canadian Setting

Survival sex work involvement as a primary risk factor for hepatitis C virus acquisition in drug-using youths in a Canadian setting

A Brief Screening Tool to Assess the Risk of Contracting HIV Infection Among Active Injection Drug Users

Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver

Sex differences in risk factors for HIV seroconversion among injection drug users: a 10-year perspective

Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic

Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users

Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users

Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users

Assessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study

Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study

Frequent needle exchange use and HIV incidence in Vancouver

Daily alcohol use as an independent risk factor for HIV seroconversion among people who inject drugs

Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs

Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size

Sharing of drug preparation equipment as a risk factor for hepatitis C

Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities

A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs

The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence

Incidence of hepatitis C virus and HIV among new injecting drug users in London: Prospective cohort study

Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination

HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination

Sex Work as an Emerging Risk Factor for Human Immunodeficiency Virus Seroconversion Among People Who Inject Drugs in the SurvUDI Network

Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France

Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia

Assessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study

Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection

Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions

High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study

High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe program

The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities

Rapid Decline in HIV Incidence Among Persons Who Inject Drugs During a Fast-Track Combination Prevention Program After an HIV Outbreak in Athens

Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment

Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul

High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes

Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users

Establishing the Melbourne Injecting Drug User Cohort Study (MIX): rationale, methods, and baseline and twelve-month follow-up results

Trends in human immunodeficiency virus incidence and risk behaviour among injection drug users in Montreal, Canada: a 16-year longitudinal study

Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis

HIV prevalence, estimated incidence, and risk behaviours among people who inject drugs in Kenya

High HIV burden among people who inject drugs in 15 Indian cities

continued growth of a rapidly expanding epidemic

High HIV incidence among persons who inject drugs in Pakistan: greater risk with needle sharing and injecting frequently among the homeless

Evaluating the impact of Mexico's drug policy reforms on people who inject drugs in

Individual, social, and environmental influences associated with HIV infection among injection drug users in Tijuana, Mexico

Acknowledgements: CA received funding from Commonwealth Scholarship Commission for his master's degree. PV, HF and JS acknowledge support from U.S. National Institute for Drug Abuse (NIDA grant number R01 DA033679, R01 DA037773, R21 DA046809 and R01  DA047952) 

ARYS participants were recruited through snowball sampling and extensive street-based outreach methods. This includes extensive street-based outreach including outreach during the night-time, and efforts to have street youth recruit their peers. Outreach has also been systematically undertaken in a range of neighbourhoods around the city where street youth are known to congregate. The streetbased recruitment approach produced a sample of youth who spent extensive time on the streets (a large proportion of whom were homeless) of Vancouver and from youth agencies and services. To be eligible, participants at recruitment must have been aged 14-26 years; used illicit drugs other than marijuana in the past 30 days; be "street involved," defined as having been homeless in the past 6 months or recently having used a service for street-involved youth (e.g., housing or nutrition support); and had to provide written informed consent; and had to provide written informed consent. For this analysis, the first record where a participant reported injection in the L6M was considered baseline. is an open prospective community-recruited cohort of PWID in Vancouver, Canada. Beginning in May 1996, active PWID (i.e. those who reported injecting drugs in the previous month) were recruited in the Greater Vancouver region on an ongoing basis throughout the study period. Recruitment strategies employ extensive street-based outreach and ''snowball'' sampling approaches. Given VIDUS is an open cohort, new participants were continuously enrolled in the cohort over the study period to replace those who died or were lost to follow-up. All participants were recruited through street outreach, word of mouth, and self-referral, and provided written informed consent prior to entering the study. Individuals were eligible if they had injected illicit drugs at least once in the previous month, were at least 18 years old, and resided in the Vancouver region.